- All sections
- C - Chemistry; metallurgy
- C12N - Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media
- C12N 15/861 - Adenoviral vectors
Patent holdings for IPC class C12N 15/861
Total number of patents in this class: 1590
10-year publication summary
49
|
62
|
103
|
153
|
108
|
128
|
151
|
167
|
117
|
38
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
The Trustees of the University of Pennsylvania | 4122 |
48 |
The Regents of the University of California | 18943 |
31 |
Glaxosmithkline Biologicals S.A. | 1701 |
30 |
The University of North Carolina at Chapel Hill | 1928 |
27 |
Janssen Vaccines & Prevention B.V. | 337 |
26 |
University of Massachusetts | 2130 |
26 |
University of Florida Research Foundation, Inc. | 3883 |
25 |
GenVec, Inc. | 64 |
24 |
The Salk Institute for Biological Studies | 436 |
19 |
Voyager Therapeutics, Inc. | 206 |
18 |
Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
16 |
Crucell Holland B.V. | 121 |
15 |
Washington University | 1473 |
14 |
Beth Israel Deaconess Medical Center, Inc. | 844 |
13 |
Genethon | 243 |
13 |
Oxford University Innovation Limited | 1421 |
13 |
Mayo Foundation for Medical Education and Research | 2981 |
12 |
Adverum Biotechnologies, Inc. | 80 |
12 |
Epicentrx, Inc. | 80 |
12 |
Prevail Therapeutics, Inc. | 61 |
12 |
Other owners | 1184 |